← All trials
NCT05543356
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 28, 2023
- Primary completion
- Dec 30, 2023
- Completion date
- Dec 30, 2023
- First posted
- Sep 16, 2022
- Last posted
- Dec 9, 2022
- Enrollment
- 0
- Arms / groups
- 8 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Murdoch UniversityLead sponsor
- The Peter Doherty InstituteCollaborator
- Murdoch UniversityOverall official - principal investigator
- Coalition for Epidemic Preparedness InnovationsCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.